A new company with a Livonia office has launched and will combine medical therapies, diagnoses, and artificial intelligence to help patients with critical illnesses.
California-based Endpoint Health, which also has a Chicago office, launched today with the intent to bring life-saving targeted therapies to patients with critical illnesses. It is focused on solutions that combine new and on-market therapeutics, companion diagnosis, and artificial intelligence into an integrated platform designed to improve outcomes.
The therapies will be for illnesses including sepsis and acute respiratory distress syndrome, which are life-threatening and often caused by serious infections, including COVID-19.
The company has received $12 million in debt and equity financing from investors including Mayfield, Y Combinator, AME Cloud Ventures, and Wireframe Ventures.
The company is led by an executive team including the co-founders of GeneWEAVE, a California-based infection detection and therapy guidance company that was acquired by Roche in a 2015 deal valued at $425 million. Endpoint is collaborating with more than 40 U.S. and international hospitals to bring the therapies to patients.
“Critical illnesses make up half of U.S. hospital mortality and over $100 billion of our annual health care spend,” says Jason Springs, co-founder and CEO of Endpoint. “Sepsis alone is associated with as many global deaths as cancer each year, and yet patients with these life-threatening illnesses still have few treatment options. The COVID-19 pandemic, which placed unprecedented numbers of patients in the ICU, has drawn the world’s attention to the desperate need for advances in this field. We need a new approach to how we understand these illnesses and how we develop and deliver treatments.”
Endpoint combines molecular and digital patient data with artificial intelligence to create therapeutic models that identify distinct patient subgroups and treatment patterns to highlight unmet therapeutic needs. The models are used to identify late-stage and on-market therapies that Endpoint can develop into targeted therapies, which will include the required tests and software to guide use. The company’s vision is to offer approved therapeutic solutions that can be targeted to each patient.